235 related articles for article (PubMed ID: 33534142)
1. Implications of a granulocyte-high glioblastoma microenvironment in immune suppression and therapy resistance
Krishnan S; Amoozgar Z; Fukumura D; Jain RK
J Pathol; 2021 Jun; 254(2):105-108. PubMed ID: 33534142
[TBL] [Abstract][Full Text] [Related]
2. Microglia/macrophages express alternative proangiogenic factors depending on granulocyte content in human glioblastoma.
Blank A; Kremenetskaia I; Urbantat RM; Acker G; Turkowski K; Radke J; Schneider UC; Vajkoczy P; Brandenburg S
J Pathol; 2021 Feb; 253(2):160-173. PubMed ID: 33044746
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
4. Myeloid Cells in Glioblastoma Microenvironment.
De Leo A; Ugolini A; Veglia F
Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
[TBL] [Abstract][Full Text] [Related]
5. Macrophages and microglia: the cerberus of glioblastoma.
Buonfiglioli A; Hambardzumyan D
Acta Neuropathol Commun; 2021 Mar; 9(1):54. PubMed ID: 33766119
[TBL] [Abstract][Full Text] [Related]
6. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
7. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.
Yin Y; Qiu S; Li X; Huang B; Xu Y; Peng Y
J Neuroinflammation; 2017 Nov; 14(1):220. PubMed ID: 29132376
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
Rivera M; Bander ED; Cisse B
World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
[TBL] [Abstract][Full Text] [Related]
9. VEGF as a modulator of the innate immune response in glioblastoma.
Turkowski K; Brandenburg S; Mueller A; Kremenetskaia I; Bungert AD; Blank A; Felsenstein M; Vajkoczy P
Glia; 2018 Jan; 66(1):161-174. PubMed ID: 28948650
[TBL] [Abstract][Full Text] [Related]
10. Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment.
Codrici E; Popescu ID; Tanase C; Enciu AM
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269652
[TBL] [Abstract][Full Text] [Related]
11. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Tamura R; Tanaka T; Akasaki Y; Murayama Y; Yoshida K; Sasaki H
Med Oncol; 2019 Nov; 37(1):2. PubMed ID: 31713115
[TBL] [Abstract][Full Text] [Related]
12. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
13. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma multiforme: novel therapeutic targets.
Muir M; Gopakumar S; Traylor J; Lee S; Rao G
Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
[TBL] [Abstract][Full Text] [Related]
15. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.
Fanelli GN; Grassini D; Ortenzi V; Pasqualetti F; Montemurro N; Perrini P; Naccarato AG; Scatena C
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804731
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
Miyazaki T; Ishikawa E; Sugii N; Matsuda M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
[TBL] [Abstract][Full Text] [Related]
18. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
19. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.
He B; Jabouille A; Steri V; Johansson-Percival A; Michael IP; Kotamraju VR; Junckerstorff R; Nowak AK; Hamzah J; Lee G; Bergers G; Ganss R
J Pathol; 2018 Jun; 245(2):209-221. PubMed ID: 29603739
[TBL] [Abstract][Full Text] [Related]
20. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
